STOCK TITAN

Kura Oncology Inc - KURA STOCK NEWS

Welcome to our dedicated news page for Kura Oncology (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kura Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kura Oncology's position in the market.

Rhea-AI Summary
Kura Oncology announces positive results from its AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
none
-
Rhea-AI Summary
Kura Oncology announces three abstracts accepted for poster presentation at upcoming conference, highlighting preclinical data supporting combination of KO-2806 with targeted therapies. Promising findings illustrate potential for enhanced antitumor activity and addressing resistance to targeted therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary
Kura Oncology presents preclinical data supporting the development of its next-generation FTI KO-2806 in combination with KRASG12C inhibitors for the treatment of KRASG12C-mutant NSCLC. The data show deepened signaling inhibition and decreased cell proliferation, leading to tumor regressions in preclinical models. The combination therapy also demonstrated enhanced duration and depth of antitumor response compared to adagrasib alone. Kura plans to dose the first patient in its Phase 1 trial of KO-2806 in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
Rhea-AI Summary
Kura Oncology to participate in Cantor Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

KURA Stock Data

1.48B
48.24M
1.75%
105.55%
13.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About KURA

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.